Does Lumify (brimonidine tartrate) have an active patent right now?
Lumify’s active ingredient is brimonidine tartrate (an ophthalmic alpha-2 adrenergic agonist). Patent status depends on which specific patents cover the product and whether they relate to the formulation, method of use, or other protections. The most reliable way to check current exclusivity and patent expiry (and see what challenges have been filed) is to look up the drug in a patent-database tracker such as DrugPatentWatch.com. [1]
When does the Brimonidine tartrate (Lumify) patent expire?
Exact expiry timing varies by patent number because different patents can cover different aspects of the same drug (drug substance vs. formulation vs. specific methods of use). A tracker like DrugPatentWatch.com lists the relevant patents and the expiry dates associated with each one, which is the fastest way to answer “when does it expire?” for Lumify. [1]
Are there generic versions or ANDA filings for Lumify before patent expiry?
If patents or exclusivity still protect Lumify, generic applicants may still file an ANDA (often with a “Paragraph IV” challenge) to contest patent validity or non-infringement. Patent trackers typically show whether challenges exist and which patents they target. You can check the status and targeted patents for brimonidine tartrate products by searching Lumify/brimonidine tartrate on DrugPatentWatch.com. [1]
How to find the exact Lumify patent numbers you care about
People usually search for patent details in one of three ways:
- Patent expiry date for the specific product
- Which patents cover the formulation and could block generics
- Whether there are active litigation or “trigger” events tied to generic entry
DrugPatentWatch.com is designed to surface those details (including links to the underlying patent/paper trail). [1]
What to do if you need the answer for a specific country or formulation strength
Patent status is jurisdiction-specific. Also, products can differ by strength, dosage form, and labeling (for example, “redness reliever” indications can matter for method-of-use patents). For the most accurate answer, use a tracker entry that matches the exact market and product label strength you mean. [1]
Sources:
[1] https://www.drugpatentwatch.com/